Experience

Davis Polk is advising Roche on its acquisition of the outstanding shares of Foundation Medicine, Inc. not already owned by Roche at a price of $137.00 per share in cash. The transaction is…

Davis Polk, together with Slaughter and May, is advising Shire plc in connection with a recommended cash and stock offer for Shire’s entire share capital by Takeda Pharmaceutical Company…

Davis Polk is advising McKesson Corporation on its acquisition of Medical Specialties Distributors, LLC from New Mountain Capital. The transaction is valued at $800 million, and is subject…

Davis Polk is advising Shire plc on the $2.4 billion sale of its Oncology business to Servier S.A.S. The transaction has been approved by the board of directors and is expected to close in…

Davis Polk is advising iKang Healthcare Group, Inc. in connection with its acquisition for $41.20 per common share or $20.60 per American Depository Share by a consortium consisting of…

Davis Polk is advising Agilent Technologies, Inc. on its acquisition of privately held Advanced Analytical Technologies, Inc. in a $250 million cash transaction. The transaction is subject…

Davis Polk is advising Roche on its $1.9 billion acquisition of Flatiron Health, Inc. The transaction, which is expected to close in the first half of 2018, is subject to customary closing…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $800 million acquisition of MPI Research Inc. The transaction, which is expected to close early in…

Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to Varian Medical Systems, Inc. in connection with its approximately A$1.6 billion acquisition of Sirtex Medical…

Davis Polk is advising TiGenix in connection with its entry into an offer and support agreement with Takeda Pharmaceutical Company Limited, pursuant to which Takeda will make a public…